Financials Amarin Corporation plc

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
0.8749 USD +1.72% Intraday chart for Amarin Corporation plc +1.82% +0.56%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,695 1,901 1,333 488.6 355.2 359.3 - -
Enterprise Value (EV) 1 7,101 1,400 1,114 270.4 156 141.8 172.8 327.3
P/E ratio -306 x -97.8 x 169 x -4.65 x -5.8 x -5.87 x -6.54 x 87.5 x
Yield - - - - - - - -
Capitalization / Revenue 17.9 x 3.1 x 2.29 x 1.32 x 1.16 x 1.61 x 1.55 x 1.2 x
EV / Revenue 16.5 x 2.28 x 1.91 x 0.73 x 0.51 x 0.63 x 0.75 x 1.1 x
EV / EBITDA -295 x -73.5 x 44.9 x -5.69 x -2.31 x -1.94 x -2.55 x -191 x
EV / FCF -600 x -63.7 x -16.7 x -1.5 x 22.7 x 6.75 x - -
FCF Yield -0.17% -1.57% -5.97% -66.8% 4.41% 14.8% - -
Price to Book 12.1 x 2.97 x 2 x 0.82 x 0.64 x 0.72 x 0.78 x -
Nbr of stocks (in thousands) 358,907 388,829 395,629 403,829 408,292 410,672 - -
Reference price 2 21.44 4.890 3.370 1.210 0.8700 0.8749 0.8749 0.8749
Announcement Date 2/25/20 2/25/21 3/1/22 3/1/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 429.8 614.1 583.2 369.2 306.9 223.8 231.2 298.4
EBITDA 1 -24.1 -19.06 24.81 -47.5 -67.43 -73.02 -67.66 -1.71
EBIT 1 -24.28 -19.66 24.22 -74.26 -67.59 -53.12 -24.45 36.98
Operating Margin -5.65% -3.2% 4.15% -20.12% -22.02% -23.73% -10.57% 12.39%
Earnings before Tax (EBT) 1 -22.48 -17.26 11.29 -103.8 -53.67 -54.88 -36.64 38.41
Net income 1 -22.64 -18 7.729 -105.8 -59.11 -60.6 -52.6 3.706
Net margin -5.27% -2.93% 1.33% -28.66% -19.26% -27.08% -22.75% 1.24%
EPS 2 -0.0700 -0.0500 0.0200 -0.2600 -0.1500 -0.1490 -0.1338 0.0100
Free Cash Flow 1 -11.84 -22 -66.53 -180.7 6.88 21 - -
FCF margin -2.76% -3.58% -11.41% -48.94% 2.24% 9.38% - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/25/20 2/25/21 3/1/22 3/1/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 142 144.5 94.63 94.44 89.88 90.24 85.98 80.17 66.06 74.71 57.05 54.56 52.81 57.32
EBITDA 1.186 15.88 -27.53 -37.48 -5.006 -3.029 -17.28 - - -4.804 - - - -
EBIT 1 1.042 15.74 -28.31 -37.62 1.427 -9.766 -17.34 -23.96 -21.45 -4.837 -11.78 -13.32 -14.66 -13.35
Operating Margin 0.73% 10.89% -29.91% -39.83% 1.59% -10.82% -20.17% -29.89% -32.47% -6.47% -20.66% -24.41% -27.76% -23.29%
Earnings before Tax (EBT) 1 -12.97 16.39 -28.35 -64.8 -3.883 -6.773 -14.5 -17.92 -18.81 -2.449 -8.638 -9.038 -9.425 -8.638
Net income 1 -13.15 14.7 -31.56 -69.96 -5.14 0.856 -16.46 -17.56 -19.31 -5.781 -12.11 -13.58 -14.7 -11.28
Net margin -9.26% 10.17% -33.35% -74.07% -5.72% 0.95% -19.15% -21.9% -29.23% -7.74% -21.23% -24.88% -27.83% -19.67%
EPS 2 -0.0300 0.0400 -0.0800 -0.1800 -0.0100 - -0.0400 -0.0400 -0.0500 -0.0100 -0.0320 -0.0380 -0.0420 -0.0360
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/3/21 3/1/22 5/4/22 8/3/22 10/27/22 3/1/23 5/3/23 8/2/23 11/1/23 2/29/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 594 501 219 218 199 217 187 32
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -11.8 -22 -66.5 -181 6.88 21 - -
ROE (net income / shareholders' equity) -5.95% -2.91% 1.19% -16.8% -5.15% -14.5% -13.3% -
ROA (Net income/ Total Assets) -3.57% -1.95% 0.76% -10.8% -3.44% -9.52% -8.33% -
Assets 1 634 924.1 1,017 977.1 1,718 636.7 631.2 -
Book Value Per Share 2 1.780 1.640 1.680 1.480 1.350 1.210 1.120 -
Cash Flow per Share - - - - - - - -
Capex 1 2.48 0.25 - 0.6 - 0.5 0.5 0.5
Capex / Sales 0.58% 0.04% - 0.16% - 0.22% 0.22% 0.17%
Announcement Date 2/25/20 2/25/21 3/1/22 3/1/23 2/29/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
0.8749 USD
Average target price
1.083 USD
Spread / Average Target
+23.82%
Consensus
  1. Stock Market
  2. Equities
  3. AMRN Stock
  4. Financials Amarin Corporation plc